MTD214

**MTD214** is an investigational long-acting injectable formulation of **tacrolimus** being developed by Midatech using its Q-Sphera sustained-release drug delivery platform for **transplant anti-rejection** use. Public company materials identify MTD214 specifically as tacrolimus and describe it as a first-in-class long-acting injectable program intended to improve the delivery and durability of immunosuppressive therapy relative to conventional tacrolimus dosing. The exact finalized formulation details, clinical pharmacology, and development progress have not been well disclosed in primary public scientific sources, so the mechanism is most appropriately inferred from tacrolimus: calcineurin inhibition leading to suppression of T-cell activation and reduced interleukin-2 signaling.

Other names

tacrolimus